Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Natalie Galanina, MD, Sonali M. Smith, MD, Chuanhong Liao, PhD, Adam M. Petrich, MD, Bernadette Libao, Ron Gartenhaus, MD, Jason R Westin, MD, Kenneth S. Cohen, MD, James Knost, MD, Walter Stadler, MD, Austin Doyle, MD, Theodore Karrison, PhD, Leo I. Gordon, MD, Andrew M Evens, DO, MS

Blood (2015) 126 (23): 3990.

https://doi.org/10.1182/blood.V126.23.3990.3990

Published: 2015

Journal Articles

Cytomegalovirus Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation with Intensive Monitoring and Modern Anti-Viral Therapy

S. Singhal, Rucha Mehta, J. Krishnamurthy, S. Duffey, O. Frankfurt, Andrew M Evens, DO, MS, J. Altman, M. Tallman, L. Gordon, S. Williams, J. Winter, J. Mehta

Blood (2008) 112 (11): 4370.

https://doi.org/10.1182/blood.V112.11.4370.4370

Published: 2008

Journal Articles

Actual (ABW) or Ideal (IBW) Body Weight to Calculate CD34+ Cell Dose in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Myeloma?

J. Krishnamurthy, V. Singh, O. Frankfurt, Andrew M Evens, DO, MS, J. Altman, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, J. Mehta

Blood (2008) 112 (11): 4455.

https://doi.org/10.1182/blood.V112.11.4455.4455

Published: 2008

Journal Articles

Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies

J. Mehta, O. Frankfurt, J. Altman, Andrew M Evens, DO, MS, L. Gordon, M. Tallman, S. Williams, J. Winter, J. Krishnamurthy, D. Grinblatt, L. Kaminer, S. Singhal

Blood (2008) 112 (11): 4386.

https://doi.org/10.1182/blood.V112.11.4386.4386

Published: 2008

Journal Articles

The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies.

V. Singh, J. Krishnamurthy, O. Frankfurt, Andrew M Evens, DO, MS, J. Altman, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, J. Mehta

Blood (2008) 112 (11): 1115.

https://doi.org/10.1182/blood.V112.11.1115.1115

Published: 2008

Journal Articles

Optimizing the CD34+ Cell Dose for Allogeneic Transplantation.

J. Mehta, Andrew M Evens, DO, MS, J. Altman, O. Frankfurt, Martin Tallman, MD, L. Gordon, S. Williams, J. Winter, J. Krishnamurthy, S. Duffey, V. Singh, R. Meagher, S. Singhal

Blood (2008) 112 (11): 1118.

https://doi.org/10.1182/blood.V112.11.1118.1118

Published: 2008

Journal Articles

The Hematopoietic Cell Transplantation Comorbidity Index: No Effect on Outcome of Reduced-Intensity Allografts.

O. Frankfurt, J. Altman, J. Krishnamurthy, Andrew M Evens, DO, MS, L. Gordon, S. Singhal, M. Tallman, S. Williams, J. Winter, S. Duffey, V. Singh, R. Meagher, J. Mehta

Blood (2008) 112 (11): 1119.

https://doi.org/10.1182/blood.V112.11.1119.1119

Published: 2008

Journal Articles

A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL).

Kevin A. David, MD, Mitchell R. Smith, MD, PhD, Izidore S. Lossos, MD, Eren Roubal, BS, Jane N. Winter, MD, Steve T. Rosen, MD, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2008) 112 (11): 2004.

https://doi.org/10.1182/blood.V112.11.2004.2004

Published: 2008

Journal Articles

Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).

Andrew M. Evens, DO, MS, Leo I. Gordon, MD, David Patton, BS, Steven T. Rosen, MD, Jane N. Winter, MD, Justin Kline, MD, Koen Van Besien, MD, Sonali M. Smith, MD

Blood (2008) 112 (11): 2005.

https://doi.org/10.1182/blood.V112.11.2005.2005

Published: 2008

Journal Articles

Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Andrew M. Evens, DO, MS, Laurie H. Sehn, MD, MPH, Pedro Farinha, MD, Paul T Schumacker, PhD, Adekunle Raji, MS, Yi Lu, MD, Beverly P. Nelson, MD, Randy D. Gascoyne, MD, Leo I. Gordon, MD

Blood (2008) 112 (11): 479.

https://doi.org/10.1182/blood.V112.11.479.479

Published: 2008

Journal Articles

Inhibition of Autophagy with 3-Methyladenine Synergistically Enhances Cellular Apoptosis Induced by the Histone Deacetylase Inhibitor PCI 24781 in Non-Hodgkin’s Lymphoma Cells

Kevin A Davi, MD, Savita Bhalla, PhD, Sheila Prachand, M.S., Andrew M Evens, DO, MS, Leo I. Gordon, MD

Blood (2008) 112 (11): 3625.

https://doi.org/10.1182/blood.V112.11.3625.3625

Published: 2008

Journal Articles

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

Andrew M. Evens, DO, MS, Kevin A. David, MD, Irene Helenowski, PhD, Sheetal M. Kircher, MD, Lauren Mauro, MD, Alla Gimelfarb, MD, Koen Van Besien, MD, Elise Hattersley, MD, Beverly P Nelson, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jamile M. Shammo, MD, FASCP, Scott E. Smith, MD, PhD, Sonali Smith, MD

Blood (2008) 112 (11): 1776.

https://doi.org/10.1182/blood.V112.11.1776.1776

Published: 2008

Journal Articles

The Diterpenoid Lactone Andrographolide (ANDRO) Stimulates Autophagy and Induces Reactive Oxygen Species (ROS)-Dependent Apoptosis in Lymphoma Cell Lines

Shuo Yang, PhD, Andrew M. Evens, DO, MS, Sheila Prachand, MS, Leo I. Gordon, MD

Blood (2008) 112 (11): 4991.

https://doi.org/10.1182/blood.V112.11.4991.4991

Published: 2008

Journal Articles

Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin’s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).

Andrew M. Evens, DO, MS, Paul T. Schumacker, PhD, Irene B. Helenowski, MS, Amar Singh, PhD, Danijela Dokic, MD, Anjeni Keswani, MD, Elizabeth Kordeluk, BS, Adekunle Raji, MS, Jane N. Winter, MD, Borko D. Jovanovic, PhD, Arne Holmgren, MD, PhD, Beverly P. Nelson, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 3587.

https://doi.org/10.1182/blood.V110.11.3587.3587

Published: 2007

Journal Articles

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Savita Bhalla, PhD, Kevin David, MD, Lauren Mauro, MD, Sheila Prachand, MS, Mint Sirisawad, Sriram Balasubramanian, PhD, Richard A. Miller, MD, Joseph Buggy, PhD, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2007) 110 (11): 3589.

https://doi.org/10.1182/blood.V110.11.3589.3589

Published: 2007

Journal Articles

Arsenic Trioxide (As 2 O 3 ) Mediated Cell Death in Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL): Investigation of Reactive Oxygen Species (ROS), Caspase, and MAP Kinase Signaling Pathways.

Savita Bhalla, PhD, Amareshwar T.K Singh, PhD, Sheila Prachand, MS, Qudsia Haque, BS, Thomas V. O’Halloran, PhD, Jane N. Winter, MD, Paul T. Schumacker, PhD, Leonidas C. Platanias, MD, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2007) 110 (11): 2576.

https://doi.org/10.1182/blood.V110.11.2576.2576

Published: 2007

Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 2558.

https://doi.org/10.1182/blood.V110.11.2558.2558

Published: 2007

Journal Articles

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Andrew M. Evens, DO, MS, Jane N. Winter, MD, Nanjiang Hou, MS, Fred Rademaker, PhD, Katalin Kelemen, MD, Beverly Nelson, MD, David Patton, BS, Olga Frankfurt, MD, Stephanie Williams, MD, Seema Singhal, MD, Martin S. Tallman, MD, Steven T. Rosen, MD, Jayesh Mehta, MD, Leo I. Gordon, MD

Blood (2006) 108 (11): 2448.

https://doi.org/10.1182/blood.V108.11.2448.2448

Published: 2006

Journal Articles

Motexafin Gadolinium (Mgd), a Redox Stress Inducer, Lowers p53 Protein but Not Message in Lymphoma Cell Lines: Mechanisms of Reactive Oxygen Species (ROS)-Mediated Apoptosis in Lymphoma.

Amareshwar Singh, PhD, Sheila Prachand, Andrew M. Evens, DO,MS, Paul Schumacker, PhD, Leo I. Gordon, MD

Blood (2006) 108 (11): 2393.

https://doi.org/10.1182/blood.V108.11.2393.2393

Published: 2006

Journal Articles

Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide’s “Off-Label” Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns.

Andrew M. Evens, DO, MS, June M. McKoy, MD, MPH, JD, Paul R. Yarnold, PhD, Kathyrn McCaffrey, BA, Charles L. Bennett, MD, PhD, MPP

Blood (2005) 106 (11): 2244.

https://doi.org/10.1182/blood.V106.11.2244.2244

Published: 2005

NARROW

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Cytomegalovirus Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation with Intensive Monitoring and Modern Anti-Viral Therapy

Actual (ABW) or Ideal (IBW) Body Weight to Calculate CD34+ Cell Dose in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Myeloma?

Factors Affecting the Results of Allogeneic Hematopoietic Stem Cell Transplantation in Hematologic Malignancies

The Effect of Increasing CD34+ Cell Doses on Time to Engraftment after Autotransplantation for Hematologic Malignancies.

Optimizing the CD34+ Cell Dose for Allogeneic Transplantation.

The Hematopoietic Cell Transplantation Comorbidity Index: No Effect on Outcome of Reduced-Intensity Allografts.

A Phase II Trial of Combination Bortezomib (Velcade®) and Rituximab for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL).

Phase I Results of Combination Gemcitabine and Bortezomib (Velcade®) for Relapsed/Refractory Nodal T-Cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL).

Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Inhibition of Autophagy with 3-Methyladenine Synergistically Enhances Cellular Apoptosis Induced by the Histone Deacetylase Inhibitor PCI 24781 in Non-Hodgkin’s Lymphoma Cells

Outcomes and a New Prognostic Model in Posttransplantation Lymphoproliferative Disorders (PTLD): Intent-to-Treat (ITT) Analysis of 81 Patients in the Post-Rituximab Era.

The Diterpenoid Lactone Andrographolide (ANDRO) Stimulates Autophagy and Induces Reactive Oxygen Species (ROS)-Dependent Apoptosis in Lymphoma Cell Lines

Hypoxia-Inducible Factor-Alpha (HIF-α) Activation in Non-Hodgkin’s Lymphoma (NHL): Relationship to the Thioredoxin Family and Correlation with Survival by Tissue Microarray (TMA).

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Arsenic Trioxide (As 2 O 3 ) Mediated Cell Death in Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL): Investigation of Reactive Oxygen Species (ROS), Caspase, and MAP Kinase Signaling Pathways.

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Motexafin Gadolinium (Mgd), a Redox Stress Inducer, Lowers p53 Protein but Not Message in Lymphoma Cell Lines: Mechanisms of Reactive Oxygen Species (ROS)-Mediated Apoptosis in Lymphoma.

Thalidomide-Associated Thromboembolism in Cancer: Reimbursement for Thalidomide’s “Off-Label” Prescribing under the 2004 Medicare Oral Pharmaceutical Demonstration Project Raises Concerns.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only